Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects
NCT06918366Phase 1Active, not recruiting
- Sponsor
- Brilliant Inspiration Biotherapeutics
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Part A - single rising dose 1 in idiopathic pulmonary fibrosis (IPF) (8 arms), sponsored by Brilliant Inspiration Biotherapeutics. Primary endpoints: Adverse Events up to 9 days and Clinically Relevant Changes in Safety Parameters up to 9 days. Started Aug 2024; status: active, not recruiting.
02
Drugs
Part A - single rising dose 1
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06918366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918366.